Form 4 holding
Director
Omada Health, Inc.
- Security class
- Common Stock
- Shares / value
- 26,655
- Estimated value
- $585,077
- Report date
- 05 Jul 2026
- Price
- $21.95
- Ownership
- Direct
Jeryl L. Hilleman
Insider Reports History
- Reporting-owner location
- Menlo Park, CA
- Latest reporting-owner signature
-
/s/ Nathan Salha, as Attorney-in-Fact for Jeryl L. Hilleman
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Jeryl L. Hilleman
Form 4 holding
Director
SI-BONE, Inc.
- Security class
- Common stock
- Shares / value
- 43,772
- Estimated value
- $552,840
- Report date
- 04 Jun 2026
- Price
- $12.63
- Ownership
- Direct
Form 4 holding
Director
NovoCure Ltd
- Security class
- Ordinary Shares
- Shares / value
- 25,471
- Estimated value
- $277,633
- Report date
- 03 Jun 2026
- Price
- $10.90
- Ownership
- Direct
Form 4 holding
Director
NovoCure Ltd
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 16,999
- Estimated value
- $101,533
- Report date
- 03 Jun 2026
- Price
- $16.30
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
Form 4 holding
Director
HilleVax, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 17 Sep 2025
- Price
- $2.06
- Ownership
- Direct
Form 4 holding
Director
CUTERA INC
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 40,000
- Estimated value
- Report date
- 24 Oct 2024
- Price
- Ownership
- Direct
- Underlying class
- COMMON STOCK
- Underlying amount
Form 4 holding
Director
HilleVax, Inc.
- Security class
- Stock Option
- Shares / value
- 22,500
- Estimated value
- Report date
- 06 Jun 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Minerva Neurosciences, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 12,500
- Estimated value
- Report date
- 27 Sep 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
NovoCure Ltd
- Security class
- Restricted Stock Units
- Shares / value
- 6,590
- Estimated value
- Report date
- 05 Jun 2024
- Price
- Ownership
- Direct
Insider Reports Filed by Jeryl L. Hilleman
4/A
OMDA
Omada Health, Inc.
- Report period
- 05 Jul 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 20 Jul 2026, 19:16
- Role
- Director
- Next action
- Open filing details
4
OMDA
Omada Health, Inc.
- Report period
- 16 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 18 Jun 2026, 16:25
- Role
- Director
- Next action
- Open filing details
4
SIBN
SI-BONE, Inc.
- Report period
- 04 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Jun 2026, 14:50
- Role
- Director
- Next action
- Open filing details
4
NVCR
NovoCure Ltd
- Report period
- 03 Jun 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 05 Jun 2026, 16:26
- Role
- Director
- Next action
- Open filing details
4
NVCR
NovoCure Ltd
- Report period
- 02 Jun 2026
- Transactions
- 1
- Transaction value
- -$46,445
- Accepted by SEC
- 03 Jun 2026, 16:53
- Role
- Director
- Next action
- Open filing details
4
OMDA
Omada Health, Inc.
- Report period
- 05 Apr 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 07 Apr 2026, 16:07
- Role
- Director
- Next action
- Open filing details
4
OMDA
Omada Health, Inc.
- Report period
- 05 Jan 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 07 Jan 2026, 17:36
- Role
- Director
- Next action
- Open filing details
4/A
OMDA
Omada Health, Inc.
- Report period
- 05 Oct 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 18 Dec 2025, 18:57
- Role
- Director
- Next action
- Open filing details
4
HLVX
HilleVax, Inc.
- Report period
- 17 Sep 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 17 Sep 2025, 16:30
- Role
- Director
- Next action
- Open filing details
4
OMDA
Omada Health, Inc.
- Report period
- 05 Jul 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 08 Jul 2025, 17:18
- Role
- Director
- Next action
- Open filing details
4
HLVX
HilleVax, Inc.
- Report period
- 23 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 25 Jun 2025, 16:13
- Role
- Director
- Next action
- Open filing details
4
OMDA
Omada Health, Inc.
- Report period
- 05 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Jun 2025, 16:13
- Role
- Director
- Next action
- Open filing details
4
SIBN
SI-BONE, Inc.
- Report period
- 05 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 06 Jun 2025, 19:45
- Role
- Director
- Next action
- Open filing details
3
OMDA
Omada Health, Inc.
- Report period
- 05 Jun 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 05 Jun 2025, 16:41
- Role
- Director
- Next action
- Open filing details
4
NVCR
NovoCure Ltd
- Report period
- 04 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 06 Jun 2025, 16:17
- Role
- Director
- Next action
- Open filing details
4
NVCR
NovoCure Ltd
- Report period
- 03 Jun 2025
- Transactions
- 1
- Transaction value
- -$17,247
- Accepted by SEC
- 04 Jun 2025, 16:17
- Role
- Director
- Next action
- Open filing details
4
CUTRQ
CUTERA INC
- Report period
- 24 Oct 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 05 Nov 2024, 16:17
- Role
- Director
- Next action
- Open filing details
4
CUTRQ
CUTERA INC
- Report period
- 12 Jul 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 16 Jul 2024, 19:06
- Role
- Director
- Next action
- Open filing details
3
CUTRQ
CUTERA INC
- Report period
- 12 Jul 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 16 Jul 2024, 19:03
- Role
- Director
- Next action
- Open filing details
4
SIBN
SI-BONE, Inc.
- Report period
- 26 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 27 Jun 2024, 17:49
- Role
- Director
- Next action
- Open filing details
4
HLVX
HilleVax, Inc.
- Report period
- 06 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 30 Apr 2025, 07:00
- Role
- Director
- Next action
- Open filing details
4
NVCR
NovoCure Ltd
- Report period
- 05 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 06 Jun 2024, 17:09
- Role
- Director
- Next action
- Open filing details
4
NERV
Minerva Neurosciences, Inc.
- Report period
- 27 Sep 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 29 Sep 2023, 08:58
- Role
- Director
- Next action
- Open filing details
4
SIBN
SI-BONE, Inc.
- Report period
- 15 Jun 2023
- Transactions
- 2
- Transaction value
- -$118,076
- Accepted by SEC
- 20 Jun 2023, 18:02
- Role
- Director
- Next action
- Open filing details
4
SIBN
SI-BONE, Inc.
- Report period
- 09 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2023, 16:27
- Role
- Director
- Next action
- Open filing details
4
HLVX
HilleVax, Inc.
- Report period
- 07 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Jun 2023, 18:36
- Role
- Director
- Next action
- Open filing details
4
NVCR
NovoCure Ltd
- Report period
- 07 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Jun 2023, 16:04
- Role
- Director
- Next action
- Open filing details
4
HLVX
HilleVax, Inc.
- Report period
- 19 Aug 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 23 Aug 2022, 16:35
- Role
- Director
- Next action
- Open filing details
4
SIBN
SI-BONE, Inc.
- Report period
- 16 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 Jun 2022, 16:02
- Role
- Director
- Next action
- Open filing details
4
SIBN
SI-BONE, Inc.
- Report period
- 13 Jun 2022
- Transactions
- 1
- Transaction value
- -$26,562
- Accepted by SEC
- 14 Jun 2022, 14:50
- Role
- Director
- Next action
- Open filing details
4
NERV
Minerva Neurosciences, Inc.
- Report period
- 10 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 28 Jun 2022, 19:36
- Role
- Director
- Next action
- Open filing details
4
NVCR
NovoCure Ltd
- Report period
- 10 Jun 2022
- Transactions
- 1
- Transaction value
- -$28,331
- Accepted by SEC
- 16 Jun 2022, 16:22
- Role
- Director
- Next action
- Open filing details
4
NVCR
NovoCure Ltd
- Report period
- 08 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2022, 16:08
- Role
- Director
- Next action
- Open filing details
3
HLVX
HilleVax, Inc.
- Report period
- 28 Apr 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 28 Apr 2022, 21:47
- Role
- Director
- Next action
- Open filing details
4
SIBN
SI-BONE, Inc.
- Report period
- 25 Jun 2021
- Transactions
- 1
- Transaction value
- -$148,324
- Accepted by SEC
- 28 Jun 2021, 17:12
- Role
- Director
- Next action
- Open filing details
4
NERV
Minerva Neurosciences, Inc.
- Report period
- 11 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Jun 2021, 17:47
- Role
- Director
- Next action
- Open filing details
4
SIBN
SI-BONE, Inc.
- Report period
- 10 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2021, 17:41
- Role
- Director
- Next action
- Open filing details
4
NVCR
NovoCure Ltd
- Report period
- 09 Jun 2021
- Transactions
- 3
- Transaction value
- -$266,713
- Accepted by SEC
- 11 Jun 2021, 16:21
- Role
- Director
- Next action
- Open filing details